

E1
✓ 2. (Three Times Amended) A method according to claim 1, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, and lipoprotein conjugates[, **antibody conjugates and antibody fragment conjugates**].

SVb
F 3
E2 18. (Three Times Amended) A method of reducing kidney retention of a protein conjugate in a patient undergoing treatment with a targeting protein conjugate comprising administering to said patient, one or more compounds selected from the group consisting of D-lysine, poly-D-lysine having a molecular weight in the range 1-60 kD, poly-L-lysine having a molecular weight in the range 1-60 kD, pharmaceutically acceptable salts thereof and carboxyl derivatives thereof, wherein said protein conjugate has a molecular weight that is not greater than about 60 kD and is not an antibody or antibody fragment conjugate,

wherein the pharmaceutically acceptable salts and carboxyl derivatives of poly-D-lysine or poly-L-lysine have a molecular weight in the range 1-60 kD,

whereby said compound or compounds reduce kidney retention of said conjugates.

19. (Three Times Amended) A method according to claim 18, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, and lipoprotein conjugates[, **antibody conjugates and antibody fragment conjugates**].